Investors interested in Conglomerates stocks should always be looking to find the best-performing companies in the group. Has Danaher (DHR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Danaher is one of 24 individual stocks in the Conglomerates sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Ra ...

文章核心观点 公司致力于通过创新产品改善生活和保护环境、建设最佳团队、保护环境等可持续发展举措,以实现长期积极影响 [2][7] 创新产品改善生活和保护环境 - 公司已更新产品开发流程,在关键阶段考虑客户的可持续性需求 [3] - 计划在2025年将产品可持续性纳入年度战略规划 [3] 建设最佳团队 - 2023年,公司全球女性员工占比达到40%,美国有色人种员工占比达到42% [4] - 2023年,公司美国新入职员工中超过三分之二为女性和/或有色人种 [4] - 2023年,公司实现了全球女性员工和美国种族少数群体员工的同工同酬 [4] 保护环境 - 公司承诺制定符合科学基础目标倡议的温室气体减排目标,包括2050年前实现价值链净零排放 [5] - 公司已制定2032年前将范围1和2温室气体排放量绝对值减少50.4%的目标 [5] - 公司启动了基于气候相关财务信息披露工作组建议的年度气候风险和机遇评估 [5] 供应链可持续性 - 2023年,公司评估和评级了占年度采购支出75%的供应商的可持续性实践,目标提高到80% [6]

文章核心观点 - 公司正与斯坦福大学合作,利用人工智能和显微镜技术,研究肿瘤微环境的复杂性,以期降低肿瘤药物临床试验的失败率 [1][2][3][4][5][6] - 该合作旨在开发一种分析引擎,能够检测肿瘤微环境中的空间、蛋白质组和代谢变化,更准确地预测肿瘤对潜在治疗方案的反应 [3][4][5][6] - 这是公司"Danaher Beacons"项目的最新成果,该项目旨在与全球知名学者合作,推动产品导向的科学研究 [7] 公司概况 - 公司是一家全球性的生命科学和诊断创新企业,致力于加速科技进步,改善人类健康 [8] - 公司拥有约63,000名员工,通过不断创新,帮助客户更快、更准确地诊断疾病,并缩短开发和交付生命改变疗法的时间和成本 [8] 行业趋势 - 肿瘤是高度可变的,不仅从肿瘤到肿瘤存在差异,同一肿瘤内部也存在差异,这导致了临床结果的不可预测性,包括临床试验的高失败率 [3] - 公司希望利用最新的空间生物学和人工智能技术,更好地捕捉和分析复杂的细胞系统,从而降低肿瘤药物开发的风险 [3][4][5]

文章核心观点 - 贝克曼-柯尔特推出了新的DxC 500i临床分析仪,这是一款集成临床化学和免疫分析的分析仪 [1][4] - DxC 500i分析仪采用了贝克曼-柯尔特最新推出的DxC 500 AU化学分析仪技术,具有六西格玛性能 [6] - DxC 500i分析仪针对卫星实验室和独立实验室的需求,提供灵活性、可扩展性和数据可互换性,并拥有广泛的化学和免疫分析检测项目 [1][3] 关于DxC 500i分析仪 - 该分析仪采用FlexMode操作,可根据样本的紧急程度优先处理免疫分析和化学检测 [5] - 新的动态样品处理器可管理重复和重新运行,无需人工干预,并在上一个样品架卸载后立即拉入新的样品架,优化了紧凑空间内的快速吞吐量 [5] - 该分析仪的直观界面支持即使是最新用户也能通过主动任务指示器、分步说明和简化的员工入职培训来操作 [5] 关于贝克曼-柯尔特公司 - 贝克曼-柯尔特是一家全球领先的诊断公司,致力于通过应用科学、技术和团队的激情与创造力来重新定义医疗诊断的未来 [8] - 公司的诊断解决方案广泛应用于复杂的临床检测,遍布全球医院、参考实验室和医生诊所 [8] - 贝克曼-柯尔特是丹纳赫公司(NYSE: DHR)的一部分,丹纳赫是一家全球科技和技术领导者 [8]

WASHINGTON, June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading ...

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service. Ms. Sawyer Montgomery, currently Vice President and Gro ...

Danaher Corporation (DHR) is posed to gain from strength in the Life Sciences segment and accretive acquisitions. However, softness in the Biotechnology segment raises concerns for the company. Decreased demand in the bioprocessing business has been weighing on the performance of the segment. Given the company’s international exposure, forex woes are weighing on its top line. What’s Aiding DHR? Business Strength: Stable demand in the academic and applied markets and strong momentum in the genomics consumabl ...

文章核心观点 - 公司正在加大对人工智能(AI)的投资,将其视为创新和生产力的驱动力 [1][2][4] - 公司任命了首席数据和人工智能官,以进一步推进公司的AI和数据战略,加速创新 [2][3] - 公司将在12月举办创新峰会,探讨AI在生物制药研发领域的潜在影响 [1][4] 公司概况 - 公司是一家全球性的科技和生命科学创新企业,致力于加速科技进步,改善人类健康 [5] - 公司拥有约63,000名员工,致力于提高诊断速度和准确性,缩短药物研发周期 [5] - 公司专注于科学卓越、创新和持续改进,为当下和未来的健康可持续发展做出贡献 [5] 人工智能战略 - 公司正通过内部能力建设、外部投资并购、与学术机构合作等方式加强AI能力 [4] - 新任命的首席数据和人工智能官拥有丰富的AI应用经验,将在公司AI战略中发挥关键作用 [2][3] - 公司将在12月的创新峰会上探讨AI在生物制药研发领域的潜在影响 [1][4]

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Danaher Q1 Earnings Beat, Biotechnology Sales Dip Y/Y Danaher ...

Danaher Corporation (DHR) has been benefiting from strength in its Life Sciences segment, driven by stable demand in the academic and applied markets, and strong momentum in the genomics consumables business. The company has been witnessing positive responses from its new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which help accelerate the drug discovery process and bring new therapies to market faster. Also, in the Diagnostics unit, new solutions like Beckman Coulter's DxI 9000 ...